Mode
Text Size
Log in / Sign up
Phase 3 N=60 Randomized Single-blind Treatment

To Access the Effects of Mucositis in Adults With Dental Implants

Mucositis

Enrolled (actual)
60
Serious AEs
0.0%
Results posted
Feb 2010
Primary outcome: Primary: Bleeding on Probing — 53.8; 52.3 Percentage of bleeding sites — p=0.05

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
Triclosan and Fluoride (Drug); Fluoride (Drug)
Age
Adult, Older Adult · 30+ yrs
Sex
All
Sponsor
Colgate Palmolive
Primary completion
Dec 2007

Outcome Measures

OutcomeResultp-value
PRIMARY
Bleeding on Probing
53.8; 52.3 0.05
PRIMARY
Mean Pocket Depth
4.4; 4.5 0.05
PRIMARY
Mean Percentage of Plaque Scores
13.2; 16.0 0.05

Summary

Clinical research for the treatment of mucositis subjects who have dental implants for a minimum of one-year.

Eligibility Criteria

Inclusion Criteria

  • Male and female subjects, ages 30-70.
  • Availability for the six-month duration of the clinical research study.
  • Good general health.
  • Subjects who have lost teeth for periodontal disease reasons and who have been restored with implants.
  • Minimum of 5 remaining teeth and a minimum of 2 implants.
  • Initial evaluation of the gingival and peri-implant mucosal tissues by determining full mouth bleeding on probing.
  • Initial plaque evaluation by determining full mouth presence/absence of plaque.
  • Signed Informed Consent Form.

Exclusion Criteria

  • Tumor(s) of the soft or hard tissues of the oral cavity.
  • Untreated periodontal disease (purulent exudate, tooth mobility, and/or extensive loss or periodontal attachment or alveolar bone).
  • Carious lesions requiring immediate restorative treatment.
  • Uncontrolled Diabetes
  • Use of antibiotics any time during the one month prior to entry into the study.
  • Untreated peri-implantitis.
  • Participation in any other clinical research study or test panel within the three months prior to entry into the study.
  • Pregnant women or women who are breast feeding.
  • History of allergies to personal care/consumer products or their ingredients.
  • Medical condition which prohibits not eating/drinking for up to 2 hours.
  • Current alcohol or drug abuse.
  • Systemic or local disease conditions that would compromise post-operative healing.
  • Regular use of anti-inflammatory drugs.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01072201). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search